BOSTON SCIENTIFIC CORP — Form 8-K
Filed November 20, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 28/100
What the filing says
On November 19, 2026, Boston Scientific priced two concurrent debt offerings: (1) $3.0B in U.S. dollar-denominated senior notes across four tranches (5.375%–5.875%, due 2029–2036) and (2) €4.25B in euro-denominated notes across six tranches (floating rate to 5.125%, due 2028–2046), all issued through its subsidiary American Medical Systems Europe B.V. with full parent guarantee. Joint bookrunners include BofA Securities, Citigroup, and J.P. Morgan; settlement December 1, 2026 (T+7 for USD, T+8 for EUR). Net proceeds will finance the Penumbra Acquisition and related fees; unuse proceeds for general corporate purposes. Special mandatory redemption required if Penumbra deal not completed by specified end date.
Why this rating
Large absolute debt issuance ($7.25B equivalent), but routine capital raise for major acquisition financing at ~4.6% of $158.7B market cap—not transformational relative to company scale.
See more from November 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.